Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Now Viewing

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Related Videos

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).